期刊
CANCER LETTERS
卷 334, 期 2, 页码 253-262出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.08.009
关键词
Paclitaxel; 2 '-Behenoyl-paclitaxel; Nanoparticle; 4T1 mouse model; Metastatic breast cancer
类别
资金
- NIH-NCI [R01 CA115197, U54 CA151652]
The aim of these studies was to develop a novel 2'-behenoyl-paclitaxel (C22-PX) conjugate nanoparticle (NP) formulation for the treatment of metastatic breast cancer. A lipophilic paditaxel derivative C22-PX was synthesized and incorporated into lipid-based NPs. Free C22-PX and its NP formulation were evaluated in a series of in vitro and in vivo studies. The results demonstrated that C22-PX NPs were much better tolerated and had significantly higher plasma and tumor AUCs compared to Taxol at the maximum tolerated dose (MTD) in a subcutaneous 4T1 mouse mammary carcinoma model. These benefits resulted in significantly improved antitumor efficacy with the NP-based formulation. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据